Guardian Bio
Dendritic cell-based platform for cancer therapy
What they do
Cancer patients often have dysfunctional dendritic cells that limit effective anti-tumor immune responses and reduce the efficacy of other cancer therapies.
A personalized dendritic cell therapy platform that derives dendritic cells from a patient’s stem cells, trains them against that patient’s tumor antigens, and reinfuses them to activate anti-tumor immunity.
Oncology clinics and hospitals treating cancer patients with advanced immunotherapies.
Founders
Ananya is Co-Founder and CEO of Guardian Bio, a company which controls immunity using dendritic cell-based therapies. She has a Bachelors in Science in Engineering from Duke and Masters in Engineering and MBA from Harvard. Her experiences span across the pharma/biotech industry in operations, engineering, project management, and early stage investing. She is passionate about delivering better therapies for patients and diversity, equity, and inclusion.
Co-founder and CSO at Guardian Bio. Ricky started his career as a marine biologist and research diver at FAU with a focus on marine natural products and drug discovery. He pursued a PhD at UCF, focused on immunology followed by a postdoc in cancer immunology and tumor microenvironment at the University of Pennsylvania. Ricky is a prolific science communicator creating educational science content for an audience of over a quarter million followers across various social media platforms.
Company timeline
- Founded2022
- YC batchSummer 2022
- StatusActive
- Team size2 people
- LocationBoston, MA, USA
Similar startups
